New weapon targets stubborn blood cancer cells
NCT ID NCT05285813
Summary
This study is testing an experimental drug called vibecotamab for patients with two types of blood cancers (AML and MDS) that haven't responded fully to standard treatments or show lingering cancer cells. The trial aims to see if vibecotamab can eliminate these remaining cancer cells or improve disease control. It involves 42 adult patients at MD Anderson Cancer Center who have specific markers on their cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.